Ethereum mainnet has successfully executed an atomic cross-chain transaction from Layer 1 to Layer 2, marking the first practical demonstration of synchronous interaction across Ethereum layers. Eduardo Antuña, a core contributor to the Ethereum Economic Zone, highlighted that this transaction proves the concept of atomic synchronous composability, which was previously theoretical. This milestone is seen as the start of efforts to improve cross-layer interactions and unify liquidity within the Ethereum ecosystem, potentially enhancing efficiency and interoperability.
Ethereum mainnet's first atomic transaction from Layer 1 to Layer 2 provides context for cryptocurrency market activity on Pluang. For readers following digital assets, here is Pluang's market snapshot as of Oct 06, 2026 12:41 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell. Notable movers include FIL (Filecoin) at Rp21.017 with a 10.73% increase and 80% buy order activity, SAND (The Sandbox) at Rp1.171 down 9.84% with a near-even sell/buy split, and EOS (EOS.IO) at Rp12.649 up 8.13%.
Ethereum (ETH) maintained stability above $2,700, marking its first weekly close above this level in nine months, signaling renewed bullish sentiment. Treasury firm BitMine expanded its Ethereum holdings by 15,112 ETH, now controlling about 4.9% of t...
Bitcoin options markets have shifted toward a bullish stance, with one-week 25-delta call options now more in demand than puts, indicating traders expect price gains. This shift, first seen in August 2026, shows calls making up about 61.4% of open in...
Binance experienced a net outflow of approximately 40,000 Bitcoin over a 15-day period, reducing its reserves from 704,800 BTC to 663,100 BTC. The weekly net outflow hit 23,100 BTC, the highest since June 2023, with a daily peak of 14,300 BTC on Octo...
Nebius Group N.V. is rated a buy due to its strategic partnership with Palantir, which positions Nebius as the preferred sovereign infrastructure provider for Palantir's enterprise AI solutions targeting regulated industries. This collaboration allow...
Poolbeg Pharma has obtained a South Korean patent for POLB 001, a treatment designed to prevent cytokine release syndrome (CRS), a serious side effect of cancer immunotherapy. The patent covers the use of p38 MAP kinase inhibitors to prevent CRS and ...
